• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

选择性增强 CCR7 作用趋化因子;短肽增强带有短碱性尾巴的趋化因子,长肽增强带有长碱性尾巴的趋化因子。

Selective Boosting of CCR7-Acting Chemokines; Short Peptides Boost Chemokines with Short Basic Tails, Longer Peptides Boost Chemokines with Long Basic Tails.

机构信息

Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Evaxion Biotech A/S, 2970 Horsholm, Denmark.

出版信息

Int J Mol Sci. 2022 Jan 26;23(3):1397. doi: 10.3390/ijms23031397.

DOI:10.3390/ijms23031397
PMID:35163323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8836243/
Abstract

The chemokine receptor CCR7 and its ligands CCL19 and CCL21 regulate the lymph node homing of dendritic cells and naïve T-cells and the following induction of a motile DC-T cell priming state. Although CCL19 and CCL21 bind CCR7 with similar affinities, CCL21 is a weak agonist compared to CCL19. Using a chimeric chemokine, CCL19, harboring the N-terminus and the C-terminus of CCL21 attached to the core domain of CCL19, we show that these parts of CCL21 act in a synergistic manner to lower ligand potency and determine the way CCL21 engages with CCR7. We have published that a naturally occurring basic C-terminal fragment of CCL21 (C21TP) boosts the signaling of both CCL19 and CCL21. Boosting occurs as a direct consequence of C21TP binding to the CCR7 N-terminus, which seems to free chemokines with basic C-termini from an unfavorable interaction with negatively charged posttranslational modifications in CCR7. Here, we confirm this using a CCL19-variant lacking the basic C-terminus. This variant displays a 22-fold higher potency at CCR7 compared to WT CCL19 and is highly unaffected by the presence of C21TP. WT CCL19 has a short basic C-terminus, CCL21 a longer one. Here, we propose a way to differentially boost CCL19 and CCL21 activity as and versions of C21TP boost CCL19 activity, whereas only a long C21TP version can boost chemokines with a full-length CCL21 C-terminus.

摘要

趋化因子受体 CCR7 及其配体 CCL19 和 CCL21 调节树突状细胞和幼稚 T 细胞的淋巴结归巢,以及随后诱导迁移的 DC-T 细胞启动状态。尽管 CCL19 和 CCL21 与 CCR7 具有相似的亲和力,但与 CCL19 相比,CCL21 是一种较弱的激动剂。使用一种嵌合趋化因子,即 CCL19,其 N 端和 C 端分别与 CCL21 的 N 端和 CCL19 的核心结构域相连,我们表明 CCL21 的这些部分以协同方式发挥作用,降低配体的效力,并决定 CCL21 与 CCR7 的结合方式。我们已经发表了一种天然存在的 CCL21 的碱性 C 末端片段(C21TP)可以增强 CCL19 和 CCL21 的信号转导。这种增强是 C21TP 与 CCR7 N 端结合的直接结果,这似乎使具有碱性 C 末端的趋化因子摆脱了与 CCR7 中带负电荷的翻译后修饰的不利相互作用。在这里,我们使用缺乏碱性 C 末端的 CCL19 变体对此进行了确认。与 WT CCL19 相比,该变体在 CCR7 上的效力提高了 22 倍,并且受 C21TP 存在的影响很小。WT CCL19 的碱性 C 末端较短,CCL21 的较长。在这里,我们提出了一种差异化增强 CCL19 和 CCL21 活性的方法,即 和 版本的 C21TP 可以增强 CCL19 的活性,而只有长的 C21TP 版本才能增强具有全长 CCL21 C 末端的趋化因子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/2414b3f9b2df/ijms-23-01397-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/b48a52b81bd3/ijms-23-01397-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/d9303e21069d/ijms-23-01397-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/e3983c4e63e2/ijms-23-01397-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/68ba8b187f3b/ijms-23-01397-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/4a4d653845d2/ijms-23-01397-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/235dc0bdec88/ijms-23-01397-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/2414b3f9b2df/ijms-23-01397-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/b48a52b81bd3/ijms-23-01397-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/d9303e21069d/ijms-23-01397-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/e3983c4e63e2/ijms-23-01397-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/68ba8b187f3b/ijms-23-01397-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/4a4d653845d2/ijms-23-01397-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/235dc0bdec88/ijms-23-01397-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca4/8836243/2414b3f9b2df/ijms-23-01397-g007.jpg

相似文献

1
Selective Boosting of CCR7-Acting Chemokines; Short Peptides Boost Chemokines with Short Basic Tails, Longer Peptides Boost Chemokines with Long Basic Tails.选择性增强 CCR7 作用趋化因子;短肽增强带有短碱性尾巴的趋化因子,长肽增强带有长碱性尾巴的趋化因子。
Int J Mol Sci. 2022 Jan 26;23(3):1397. doi: 10.3390/ijms23031397.
2
The C-terminal peptide of CCL21 drastically augments CCL21 activity through the dendritic cell lymph node homing receptor CCR7 by interaction with the receptor N-terminus.CCL21 的 C 末端肽通过与受体 N 端相互作用,极大地增强了 CCL21 活性,通过树突状细胞淋巴节点归巢受体 CCR7。
Cell Mol Life Sci. 2021 Nov;78(21-22):6963-6978. doi: 10.1007/s00018-021-03930-7. Epub 2021 Sep 29.
3
Biased Signaling of CCL21 and CCL19 Does Not Rely on N-Terminal Differences, but Markedly on the Chemokine Core Domains and Extracellular Loop 2 of CCR7.CCL21 和 CCL19 的偏向信号传递不依赖于 N 端差异,而是明显依赖于 CCR7 的趋化因子核心结构域和细胞外环 2。
Front Immunol. 2019 Sep 13;10:2156. doi: 10.3389/fimmu.2019.02156. eCollection 2019.
4
Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes.趋化因子受体CCR7在白细胞中由其配体CCL19和CCL21引发的常见且有偏向性的信号通路。
J Leukoc Biol. 2016 Jun;99(6):869-82. doi: 10.1189/jlb.2MR0815-380R. Epub 2016 Jan 4.
5
CCL19 with CCL21-tail displays enhanced glycosaminoglycan binding with retained chemotactic potency in dendritic cells.CCL19 与 CCL21 尾缀融合后增强了糖胺聚糖结合能力,同时保持了对树突状细胞的趋化活性。
J Leukoc Biol. 2018 Aug;104(2):401-411. doi: 10.1002/JLB.2VMA0118-008R. Epub 2018 May 16.
6
Fluorescently Tagged CCL19 and CCL21 to Monitor CCR7 and ACKR4 Functions.荧光标记的 CCL19 和 CCL21 用于监测 CCR7 和 ACKR4 功能。
Int J Mol Sci. 2018 Dec 4;19(12):3876. doi: 10.3390/ijms19123876.
7
Arrestin 3 mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21.在CCL19而非CCL21连接后,抑制蛋白3介导CCR7的内吞作用。
J Immunol. 2008 Oct 1;181(7):4723-32. doi: 10.4049/jimmunol.181.7.4723.
8
Dendritic cell chemotaxis in 3D under defined chemokine gradients reveals differential response to ligands CCL21 and CCL19.在三维条件下,定义趋化因子梯度下的树突状细胞趋化作用揭示了对配体 CCL21 和 CCL19 的不同反应。
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5614-9. doi: 10.1073/pnas.1014920108. Epub 2011 Mar 21.
9
Heparin Specifically Interacts with Basic BBXB Motifs of the Chemokine CCL21 to Define CCR7 Signaling.肝素特异性结合趋化因子 CCL21 的碱性 BBXB 基序来定义 CCR7 信号。
Int J Mol Sci. 2023 Jan 14;24(2):1670. doi: 10.3390/ijms24021670.
10
CCR7 Sulfotyrosine Enhances CCL21 Binding.CCR7 硫酸化酪氨酸增强 CCL21 结合。
Int J Mol Sci. 2017 Aug 25;18(9):1857. doi: 10.3390/ijms18091857.

引用本文的文献

1
Chemokine Receptor N-Terminus Charge Dictates Reliance on Post-Translational Modifications for Effective Ligand Capture and Following Boosting by Defense Peptides.趋化因子受体 N 端电荷决定了对翻译后修饰的依赖,以有效捕获配体,并随后被防御肽增强。
Int J Mol Sci. 2024 Oct 9;25(19):10854. doi: 10.3390/ijms251910854.
2
NMR indicates the N-termini of PSGL1 and CCR7 bind competitively to the chemokine CCL21.核磁共振表明,P选择素糖蛋白配体1(PSGL1)和趋化因子受体7(CCR7)的N端与趋化因子CCL21竞争性结合。
Biochem Biophys Rep. 2023 Jul 29;35:101524. doi: 10.1016/j.bbrep.2023.101524. eCollection 2023 Sep.
3
Heparin Specifically Interacts with Basic BBXB Motifs of the Chemokine CCL21 to Define CCR7 Signaling.

本文引用的文献

1
The C-terminal peptide of CCL21 drastically augments CCL21 activity through the dendritic cell lymph node homing receptor CCR7 by interaction with the receptor N-terminus.CCL21 的 C 末端肽通过与受体 N 端相互作用,极大地增强了 CCL21 活性,通过树突状细胞淋巴节点归巢受体 CCR7。
Cell Mol Life Sci. 2021 Nov;78(21-22):6963-6978. doi: 10.1007/s00018-021-03930-7. Epub 2021 Sep 29.
2
The Prevalence of Gingival Dendritic Cell Subsets in Periodontal Patients.牙周病患者牙龈树突状细胞亚群的流行率。
J Dent Res. 2021 Nov;100(12):1330-1336. doi: 10.1177/00220345211004864. Epub 2021 Apr 26.
3
G Protein-Coupled Receptors in the Sweet Spot: Glycosylation and other Post-translational Modifications.
肝素特异性结合趋化因子 CCL21 的碱性 BBXB 基序来定义 CCR7 信号。
Int J Mol Sci. 2023 Jan 14;24(2):1670. doi: 10.3390/ijms24021670.
处于关键位置的G蛋白偶联受体:糖基化及其他翻译后修饰
ACS Pharmacol Transl Sci. 2020 Mar 17;3(2):237-245. doi: 10.1021/acsptsci.0c00016. eCollection 2020 Apr 10.
4
Structural Features of an Extended C-Terminal Tail Modulate the Function of the Chemokine CCL21.结构特征的一个扩展的 C 端尾部调节趋化因子 CCL21 的功能。
Biochemistry. 2020 Apr 7;59(13):1338-1350. doi: 10.1021/acs.biochem.0c00047. Epub 2020 Mar 26.
5
Biased Signaling of CCL21 and CCL19 Does Not Rely on N-Terminal Differences, but Markedly on the Chemokine Core Domains and Extracellular Loop 2 of CCR7.CCL21 和 CCL19 的偏向信号传递不依赖于 N 端差异,而是明显依赖于 CCR7 的趋化因子核心结构域和细胞外环 2。
Front Immunol. 2019 Sep 13;10:2156. doi: 10.3389/fimmu.2019.02156. eCollection 2019.
6
Trans-sialidase Associated with Atherosclerosis: Defining the Identity of a Key Enzyme Involved in the Pathology.转涎酸酶与动脉粥样硬化:确定参与病理过程的关键酶的特性。
Curr Drug Targets. 2019;20(9):938-941. doi: 10.2174/1389450120666190308111619.
7
CCR7 Is Recruited to the Immunological Synapse, Acts as Co-stimulatory Molecule and Drives LFA-1 Clustering for Efficient T Cell Adhesion Through ZAP70.CCR7 被招募到免疫突触中,作为共刺激分子通过 ZAP70 作用并驱动 LFA-1 聚集,从而实现有效的 T 细胞黏附。
Front Immunol. 2019 Jan 14;9:3115. doi: 10.3389/fimmu.2018.03115. eCollection 2018.
8
Evaluation and extension of the two-site, two-step model for binding and activation of the chemokine receptor CCR1.评价和扩展趋化因子受体 CCR1 的结合和激活的两点两步模型。
J Biol Chem. 2019 Mar 8;294(10):3464-3475. doi: 10.1074/jbc.RA118.006535. Epub 2018 Dec 19.
9
Mapping the O-glycoproteome using site-specific extraction of O-linked glycopeptides (EXoO).利用 O-连接糖肽的特异性提取(EXoO)绘制 O-糖蛋白组图谱。
Mol Syst Biol. 2018 Nov 20;14(11):e8486. doi: 10.15252/msb.20188486.
10
Current Concepts of Antigen Cross-Presentation.抗原交叉呈递的当前概念
Front Immunol. 2018 Jul 16;9:1643. doi: 10.3389/fimmu.2018.01643. eCollection 2018.